Update on eVOLVE-Lung02 Phase III trial
AstraZeneca said it is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy as first-line treatment for metastatic NSCLC with PD-L1 <50%. The IDMC recommended stopping after planned review showed volrustomig unlikely to meet dual primary endpoints PFS and OS versus pembrolizumab plus chemotherapy in PD-L1 <1% patients. Safety was consistent with known profiles.
How this was made
The 30-second read
Why it matters
The IDMC’s planned review concluded volrustomig combination is unlikely to meet dual primary endpoints (PFS and OS) in the PD-L1 negative (<1%) primary analysis population, leading AstraZeneca to discontinue the trial.
Market read
A concrete clinical development setback for AstraZeneca’s volrustomig program in first-line mNSCLC, with immediate sentiment impact and longer-term implications for IO bispecific strategy validation.
What to watch
The article notes other Phase III volrustomig trials continue (cervical cancer, head and neck squamous cell carcinoma, mesothelioma), which could offset sentiment if upcoming readouts are strong.
Background
eVOLVE-Lung02 is a Phase III, randomized open-label trial of volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic NSCLC with PD-L1 <50% (primary analysis PD-L1 <1%).
Ticker impact
AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial after the IDMC found volrustomig plus chemo unlikely to meet PFS or OS endpoints.
Likely modest-to-moderate negative reaction, with focus shifting to remaining Phase III programs and other IO assets.
The article discloses a clear, decision-level clinical development setback (IDMC recommendation) but does not provide financial guidance or quantify commercial impact.
Market effects
Reinforces the risk of PD-1/CTLA-4 bispecific strategies failing to beat immunotherapy plus chemo in PD-L1-defined NSCLC subgroups.
Limited, primarily affects European biotech/biopharma sentiment tied to oncology trial outcomes.
Moderate read-through to global immuno-oncology trial design and endpoint expectations in mNSCLC.
Counterpoint
Discontinuation may free resources for other indications where volrustomig has better probability of success, limiting long-term damage to the platform.
Key entities
- companyAstraZeneca
Discontinuing the eVOLVE-Lung02 Phase III trial based on IDMC recommendation after endpoint underperformance risk.
- drugvolrustomig
Dual checkpoint inhibitor bispecific antibody targeting PD-1 and CTLA-4, evaluated in combination with chemotherapy.
- committeeIndependent Data Monitoring Committee (IDMC)
Recommended discontinuation after planned review of trial data.
